Nasal spray could tame brain inflammation in early Alzheimer's
NCT ID NCT06489548
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a nasal spray called foralumab in 16 people with early Alzheimer's or mild cognitive impairment. The spray aims to reduce brain inflammation by calming overactive immune cells. Participants will use the spray three times a week for eight weeks and have brain scans, memory tests, and blood draws over six months to check safety and effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMERS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Alzheimer Research and Treatment, Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple questionnaire empower dementia caregivers after hospital stays?
- Can a simple test predict Alzheimer's before symptoms worsen?
- Can a Voice-Based app map healthy brain aging across 80 years?
- Can Real-World data uncover hidden risks of the Alzheimer's drug LEQEMBI?
- Could sharing lived experiences ease the burden of dementia care?
- A new tool aims to shield dementia patients from neglect